Japan · Delayed Price · Currency is JPY Takara Bio Statistics
Total Valuation
Takara Bio has a market cap or net worth of JPY 137.76 billion. The enterprise value is 128.59 billion.
| Market Cap | 137.76B |
| Enterprise Value | 128.59B |
Important Dates
The last earnings date was Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Takara Bio has 120.42 million shares outstanding.
| Current Share Class | 120.42M |
| Shares Outstanding | 120.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 6.72% |
| Float | 14.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.42 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 38.46 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.19 |
| EV / EBITDA | 236.38 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.76, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.76 |
| Quick Ratio | 4.01 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 20.19 |
| Debt / FCF | -1.22 |
| Interest Coverage | -8.21 |
Financial Efficiency
Return on equity (ROE) is -8.69% and return on invested capital (ROIC) is -5.14%.
| Return on Equity (ROE) | -8.69% |
| Return on Assets (ROA) | -2.31% |
| Return on Invested Capital (ROIC) | -5.14% |
| Return on Capital Employed (ROCE) | -3.80% |
| Weighted Average Cost of Capital (WACC) | 6.43% |
| Revenue Per Employee | 22.66M |
| Profits Per Employee | -5.40M |
| Employee Count | 1,779 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.67 |
Taxes
In the past 12 months, Takara Bio has paid 352.00 million in taxes.
| Income Tax | 352.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.54% in the last 52 weeks. The beta is 0.43, so Takara Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +43.54% |
| 50-Day Moving Average | 1,142.84 |
| 200-Day Moving Average | 976.48 |
| Relative Strength Index (RSI) | 64.76 |
| Average Volume (20 Days) | 322,275 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Takara Bio had revenue of JPY 40.32 billion and -9.60 billion in losses. Loss per share was -79.72.
| Revenue | 40.32B |
| Gross Profit | 20.26B |
| Operating Income | -4.78B |
| Pretax Income | -9.20B |
| Net Income | -9.60B |
| EBITDA | 544.00M |
| EBIT | -4.78B |
| Loss Per Share | -79.72 |
Balance Sheet
The company has 20.45 billion in cash and 10.98 billion in debt, with a net cash position of 9.47 billion or 78.63 per share.
| Cash & Cash Equivalents | 20.45B |
| Total Debt | 10.98B |
| Net Cash | 9.47B |
| Net Cash Per Share | 78.63 |
| Equity (Book Value) | 103.97B |
| Book Value Per Share | 860.90 |
| Working Capital | 37.09B |
Cash Flow
In the last 12 months, operating cash flow was 3.58 billion and capital expenditures -12.60 billion, giving a free cash flow of -9.02 billion.
| Operating Cash Flow | 3.58B |
| Capital Expenditures | -12.60B |
| Depreciation & Amortization | 5.32B |
| Net Borrowing | 9.74B |
| Free Cash Flow | -9.02B |
| FCF Per Share | -74.88 |
Margins
Gross margin is 50.25%, with operating and profit margins of -11.85% and -23.81%.
| Gross Margin | 50.25% |
| Operating Margin | -11.85% |
| Pretax Margin | -22.82% |
| Profit Margin | -23.81% |
| EBITDA Margin | 1.35% |
| EBIT Margin | -11.85% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 17.00, which amounts to a dividend yield of 1.49%.
| Dividend Per Share | 17.00 |
| Dividend Yield | 1.49% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 1.49% |
| Earnings Yield | -6.97% |
| FCF Yield | -6.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 29, 2011. It was a forward split with a ratio of 400.
| Last Split Date | Mar 29, 2011 |
| Split Type | Forward |
| Split Ratio | 400 |
Scores
Takara Bio has an Altman Z-Score of 3.09 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.09 |
| Piotroski F-Score | 2 |